The impacts of insulin degludec U100 (Deg‐100) and insulin glargine U300 (Gla‐300) on glycemic variability (GV) in patients with type 1 diabetes, as well as the impact of major nutrient components on GV in these patients, remain unclear. The gene discussed is INS; the disease is type 1 diabetes mellitus.